Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$38.27 +5.3%	$39.55	$26.20 ▼ $63.50	$1.76B	1.43	565,052 shs	644,589 shs
BEAM Beam Therapeutics	$16.64 +3.9%	$18.74	$13.52 ▼ $35.25	$1.68B	2.22	2.52 million shs	2.39 million shs
CGEM Cullinan Therapeutics	$8.19 +6.8%	$7.80	$6.85 ▼ $19.89	$483.78M	-0.08	381,468 shs	629,410 shs
DYN Dyne Therapeutics	$12.58 +2.9%	$10.23	$6.36 ▼ $46.81	$1.79B	1.08	3.04 million shs	2.30 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+2.63%	-6.25%	-3.06%	-20.86%
BEAM Beam Therapeutics	0.00%	-6.62%	-23.39%	-1.13%	-37.93%
CGEM Cullinan Therapeutics	0.00%	+6.92%	+0.12%	+4.87%	-54.58%
DYN Dyne Therapeutics	0.00%	+1.62%	+26.43%	+7.61%	-72.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.7747 of 5 stars	4.4	3.0	2.6	4.2	0.0
BEAM Beam Therapeutics	2.2261 of 5 stars	3.5	0.0	2.7	2.5	0.6
CGEM Cullinan Therapeutics	1.9401 of 5 stars	3.5	0.0	2.7	1.7	0.6
DYN Dyne Therapeutics	3.6298 of 5 stars	4.5	1.0	2.8	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.86	Moderate Buy	$99.00	158.69% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	191.19% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$26.80	227.23% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	168.68% Upside

Current Analyst Ratings Breakdown

Latest CGEM, BEAM, DYN, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
8/18/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$35.00 ➝ $28.00
8/14/2025	APGE Apogee Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
BEAM Beam Therapeutics	$63.52M	26.50	N/A	N/A	$8.86 per share	1.88
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	11/11/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
CGEM Cullinan Therapeutics	-$167.38M	-$3.23	N/A	N/A	N/A	N/A	-36.56%	-34.82%	11/6/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	11/11/2025 (Estimated)

Latest CGEM, BEAM, DYN, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/7/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.83	-$1.07	-$0.24	-$1.07	N/A	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
BEAM Beam Therapeutics	N/A	6.75	6.75
CGEM Cullinan Therapeutics	N/A	9.83	9.83
DYN Dyne Therapeutics	0.17	16.83	16.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BEAM Beam Therapeutics	99.68%
CGEM Cullinan Therapeutics	86.31%
DYN Dyne Therapeutics	96.68%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
BEAM Beam Therapeutics	3.50%
CGEM Cullinan Therapeutics	6.07%
DYN Dyne Therapeutics	20.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
CGEM Cullinan Therapeutics	30	59.07 million	55.49 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	112.72 million	Optionable

CGEM, BEAM, DYN, and APGE Headlines

Recent News About These Companies

Candriam S.C.A. Acquires 61,973 Shares of Dyne Therapeutics, Inc. $DYN

2 hours ago | marketbeat.com

Aberdeen Group plc Boosts Stock Position in Dyne Therapeutics, Inc. $DYN

August 23 at 4:42 AM | marketbeat.com

Algert Global LLC Grows Holdings in Dyne Therapeutics, Inc. $DYN

August 21, 2025 | marketbeat.com

Deutsche Bank AG Grows Stake in Dyne Therapeutics, Inc. $DYN

August 20, 2025 | marketbeat.com

Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT

August 20, 2025 | msn.com

Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy

August 18, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

August 17, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

August 16, 2025 | prnewswire.com

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

August 14, 2025 | ajmc.comA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

August 13, 2025 | globenewswire.com

Dyne Therapeutics Advances DMD Treatment with DYNE-251 Study

August 13, 2025 | tipranks.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from Analysts

August 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

August 11, 2025 | prnewswire.com

XTX Topco Ltd Takes $330,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

August 11, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

August 9, 2025 | globenewswire.com

Dyne Therapeutics (NASDAQ:DYN) Sees Strong Trading Volume - Here's Why

August 7, 2025 | marketbeat.com

Oppenheimer Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $13.00

August 7, 2025 | marketbeat.com

Dyne Therapeutics trading halted, volatility trading pause

August 7, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

August 6, 2025 | prnewswire.com

Dyne Therapeutics Gains FDA Breakthrough Designation for DYNE-251

August 5, 2025 | theglobeandmail.com

DYNE-251 for DMD granted FDA breakthrough therapy designation

August 5, 2025 | musculardystrophynews.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CGEM, BEAM, DYN, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$38.27 +1.92 (+5.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$37.26 -1.02 (-2.65%)

As of 04:20 AM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$16.64 +0.63 (+3.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$16.86 +0.22 (+1.35%)

As of 06:56 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Cullinan Therapeutics NASDAQ:CGEM

$8.19 +0.52 (+6.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.46 +0.28 (+3.36%)

As of 08/22/2025 06:30 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$12.58 +0.36 (+2.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.46 +0.88 (+7.00%)

As of 06:57 AM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time